NEWS & EVENTS

Catalent today welcomed the recent announcement by Phathom Pharmaceuticals that the U.S. Food and Drug Administration has approved both VOQUEZNA™ TRIPLE PAK™ and VOQUEZNA™ DUAL PAK™ for the treatment of Helicobacter pylori infection in adults.

Catalent and MigVax today announced that they have signed a development agreement to leverage Catalent’s proprietary Zydis® Bio orally disintegrating tablet technology for delivering the MigVax-101 vaccine.

Catalent today announced that it has successfully completed a significant expansion of its nasal capabilities at its Morrisville, North Carolina, facility, for the development and manufacturing of unit and bi-dose nasal spray products.

The UpTempo Virtuoso platform streamlines many time-consuming steps in AAV manufacturing to significantly reduce the timeline from gene to clinic and enable rapid first-in-human clinical evaluation.

Ethicann today announced that it is to commence full CGMP manufacturing scale-up of its proprietary THC 2.7 mg : CBD 2.5mg Zydis® sublingual ODT to treat MS spasticity.

Catalent today announced that it has successfully completed a significant expansion of its nasal capabilities at its Morrisville, North Carolina, facility, for the development and manufacturing of unit and bi-dose nasal spray products.

Catalent today announced that it has acquired from Erytech Pharma its state-of-the-art, commercial-scale cell therapy manufacturing facility in Princeton, New Jersey, for $44.5 million.

The project will serve the industry’s robust biologics pipeline across various modalities with new bioreactors, syringe filling lines, and additional lyophilization capacity, supported by quality control laboratories and complex automated packaging.

Catalent today announced that it has completed the installation and commissioning of four new high throughput ‘high-bay’ CGMP manufacturing suites at its facility in Kansas City, Missouri, to increase its capacity and capabilities for producing oral solid dose forms.